The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation - Effect of interleukin 6

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 905-910

  Kruithof, Egbert K O ^a,d   Mestries, Jean Claude ^b   Gascon, Marie Paule ^c   Ythier, Arnaud ^c  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b CENTRE DE RECHERCHES   (France)

^c Serono International SA   (Switzerland)

^d Faculty of Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; D DIMER; FIBRINOGEN; FIBRINOPEPTIDE A; INTERLEUKIN 6; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOSIS;

EID: 0030978393     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656076     Document Type: Article

References (23)

1. Hardaway RM. Organ damage in shock, disseminated intravascular coagulation, and stroke. Compr Ther 1992; 18: 17-21.
2. Levi M, Ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-9.
3. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in baboons. J Clin Invest 1987; 79: 918-25.
4. Emerson TE, Fournel MA, Redens TB, Taylor FB. Efficacy of antithrombin 111 supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989; 87, suppl 3b: 27-35.
5. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-60.
6. Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am J Hematol 1991; 36: 176-83.
7. Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis 1994; 5: 829-32.
8. Giles AR, Nesheim ME, Herring SW, Hoogendoom H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990; 63: 476-81.
9. Wada H, Tanigawa M, Wakita Y, Nakase T, Minamikawa K, Kaneko T, Ohiwa M, Kageyama S, Kobayashi T, Noguchi T, Deguchi K, Shirakawa S. Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1993; 4: 583-90.
10. Van der Poll T, Büller HR, Ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, Ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
11. Van der Poll T, Levi M, Hack CE, Ten Cate H, Van Deventer SJH, Eerenberg AJM, De Groot ER, Jansen J, Gallati H, Büller HR, Ten Cate JW, Aarden LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9.
12. Mestries JC, Kruithof EKO, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994; 5: 275-81.
13. Jansen PM, Boermeester MA, Fischer E, De Jong IW, Van der Poll T, Moldawer LL, Hack CE, Lowry SF. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation and the release of secretory type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin 1alpha adminstration and during lethal bacteremia. Blood 1995; 86: 1027-34.
14. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, Ten Cate JW. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88: 587-94.
15. Podor TJ, Hirsh J, Gelehrter TD, Zeheb R, Torry D, Guigoz Y, Sierra F, Gauldie J. Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6-and hepatocyte-dependent synthesis. J Immunol 1993; 150: 225-35.
16. Rubin N, Colman RW. Disseminated intravascular coagulation. Approach to treatment. Drugs 1992 ; 44: 963-71.
17. Bauer KA, Weitz JI. Laboratory markers of coagulation and fibrinolysis. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds, Lippincott Company, Philadelphia 1994. 3rd edition, pp 1197-202.
18. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989; 74: 1025-30.
19. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin 111 but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
20. Van den Eijnden-Schrauwen Y, Kooistra T, De Vries REM, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and rats in vivo: evidence for a dynamic storage pool. Blood 1995; 85: 3510-7.
21. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1994; 342: 1076-9.
22. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo JC, the ECAT study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
23. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.